Leerink Swann reiterated their outperform rating on shares of Epizyme Inc. (NASDAQ:EPZM) in a research report report published on Friday morning.

A number of other equities research analysts have also recently weighed in on EPZM. Zacks Investment Research raised shares of Epizyme from a hold rating to a buy rating and set a $12.00 price target for the company in a research report on Monday, July 11th. Cowen and Company reissued a buy rating on shares of Epizyme in a research report on Monday, June 20th. Royal Bank Of Canada reissued an outperform rating and issued a $26.00 price target on shares of Epizyme in a research report on Monday, June 20th. HC Wainwright reissued a buy rating on shares of Epizyme in a research report on Monday, June 20th. Finally, Mizuho reissued a buy rating and issued a $18.00 price target on shares of Epizyme in a research report on Monday, June 20th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Epizyme has a consensus rating of Buy and an average price target of $23.11.

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Epizyme (NASDAQ:EPZM) traded down 1.68% during midday trading on Friday, hitting $9.36. The stock had a trading volume of 122,367 shares. The stock’s market cap is $542.47 million. The stock has a 50 day moving average of $8.70 and a 200 day moving average of $10.14. Epizyme has a 12 month low of $7.02 and a 12 month high of $18.29.

Epizyme (NASDAQ:EPZM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. Epizyme had a negative net margin of 5,174.49% and a negative return on equity of 43.05%. Analysts expect that Epizyme will post ($2.20) EPS for the current fiscal year.

In other news, insider Robert A. Copeland sold 4,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $10.37, for a total value of $41,480.00. Following the sale, the insider now directly owns 35,538 shares in the company, valued at $368,529.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 25.40% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in EPZM. Dynamic Technology Lab Private Ltd acquired a new stake in Epizyme during the second quarter valued at approximately $104,000. HBK Investments L P acquired a new stake in Epizyme during the first quarter valued at approximately $149,000. State Board of Administration of Florida Retirement System raised its stake in Epizyme by 15.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 15,347 shares of the biopharmaceutical company’s stock valued at $157,000 after buying an additional 2,102 shares in the last quarter. American International Group Inc. raised its stake in Epizyme by 36.2% in the second quarter. American International Group Inc. now owns 23,167 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 6,155 shares in the last quarter. Finally, Woodstock Corp acquired a new stake in Epizyme during the second quarter valued at approximately $282,000. Institutional investors and hedge funds own 80.79% of the company’s stock.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

5 Day Chart for NASDAQ:EPZM

Receive News & Stock Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related stocks with our FREE daily email newsletter.